Back to search

Article

Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges

2023-11-13

Abstract excerpt

Pathologic angiogenesis is responsible for much of the vision loss that stems from several chorioretinal vascular diseases including neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Because vascular endothelial growth factor (VEGF) serves as a pivotal angiogenic molecule, it has emerged as the primary target for therapeutic drugs. Current anti-VEGF t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8e6bb0af-37b9-54df-b02d-9e4fdb2b3309
DOI
10.20944/preprints202311.0789.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesDOI 10.20944/preprints202311.0789.v1
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialistsSemantic proximity
Targeting vascular endothelial growth factor using retinal gene therapySemantic proximity
Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future ProspectsSemantic proximity
Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity
Clinical Efficacy and Safety of Anti-vascular Biosimilars Compared to Reference Anti-vascular for neovascular age-related macular degeneration: A Systematic Review, Meta-Analysis and Meta-regression.Semantic proximity
Persistent Cytotoxic Immune Signaling in Anti-VEGF–Treated Neovascular Age-Related Macular DegenerationSemantic proximity
Gene therapy for age-related macular degenerationSemantic proximity
Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnologySemantic proximity
VEGF-A: a critical regulator of blood vessel growthSemantic proximity
Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily betterSemantic proximity
Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from TaiwanSemantic proximity
Clinical care and therapeutic practice of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and effectiveness of faricimab in treatment-naive patients in Germany - ZEUS research projectSemantic proximity
Select a neighboring publication to make it the new centre.